Lexaria Bioscience

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. Its products can be used with APIs encompassing fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) pain medications, hormones, phosphodiesterase inhibitors, antivirals, nicotine and its analogs, and all cannabinoids including tetrahydrocannabinol (THC) for therapeutic indications, as well as hypertension, SARS-CoV-2/COVID-19, and HIV/AIDS. It operates through the following segments: IP Licensing, B2B Product, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. Its products can be used with APIs fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) pain medications, hormones, phosphodiesterase inhibitors, antivirals, nicotine and its analogs, and all cannabinoids including tetrahydrocannabinol (THC) for therapeutic indications, as well as hypertension, SARS-CoV-2/COVID-19, and HIV/AIDS. It operates through the following segments: IP Licensing, B2B Product, Research and Development, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

DehydraTECH delivers equivalent quantity of oral THC three times faster: 15 minutes vs. 45 minutes KELOWNA, BC / ACCESSWIRE / October 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its recent oral tetrahydrocannabinol ("THC") absorption study THC-A21-1 revealed that DehydraTECHTM-THC delivered via oral ingestion required only 15 minutes to deliver THC levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls.

Lexaria's Technology Proven to Deliver Oral THC More Effectively

New York, New York--(Newsfile Corp. - October 5, 2021) - PCG Digital -- Lexaria Bioscience Corp (NASDAQ: LEXX) is making headlines again this week. In a study conducted by a leading independent testing facility, DehydraTECH™ 2.0 nicotine pouches easily outperformed generic nicotine benzoate pouches, hitting peak delivery rates within eight minutes, and then again at thirty minutes. The generic pouches hit peak at forty-five minutes.It's a significant disparity when comparing two similar products, but Lexaria...

DehydraTECH(TM) Nicotine Pouches Could Make Smoking Obsolete

DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls Peak levels achieved were up to 10x higher than controls KELOWNA, BC / ACCESSWIRE / October 5, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its recent oral nicotine absorption study NIC-A21-1 revealed that DehydraTECHTM-nicotine delivered via the oral pouch product format required only 2 to 4 minutes to deliver nicotine levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls. DehydraTECH-nicotine also reached statistically significant peak blood plasma levels up to 10-fold higher overall than controls (p=0.004) while still clearing from blood virtually as quickly as the controls.

Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results

Aurora Cannabis

Applied DNA Sciences

Canopy Growth

Flora Growth Corp

Akerna Corp

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.

5 Cannabis Stocks That Lit Up Wall Street This Week

KELOWNA, BC / ACCESSWIRE / September 9, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces today that Chairman & CEO Chris Bunka will present at the 23rd Annual H.C. Wainwright Global Investment Conference which is being held virtually from September 13-15, 2021.

Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Lexaria Bioscience Corp (NASDAQ: LEXX) has formally begun the process towards an Investigational New Drug (IND) application filing with the FDA for its DehydraTECH-processed cannabidiol (DehydraTECH-CBD) as a prospective pharmaceutical treatment for hypertension. Lexaria has recruited a consultancy group that will help prepare Lexaria for a pre-IND meeting with the FDA and design the necessary IND-enabling work.

Lexaria Starts IND-Enabling Program For DehydraTECH-CBD For Hypertension

Positive results using DehydraTECH-CBD support progressing to FDA IND application KELOWNA, BC / ACCESSWIRE / September 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms today announced it is formally beginning the process towards an Investigational New Drug ("IND") application filing with the Food and Drug Administration ("FDA") with its DehydraTECH-processed cannabidiol ("DehydraTECH-CBD") as a prospective registered pharmaceutical treatment for hypertension. Lexaria has retained the services of an expert regulatory affairs and quality assurance consultancy group that will help prepare Lexaria for a pre-IND meeting with the FDA, as well as with designing the necessary non-clinical, clinical and related product development IND-enabling work to be completed in advance of the IND filing.

Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension

Vancouver, British Columbia--(Newsfile Corp. - September 7, 2021) - Lexaria Bioscience (NASDAQ: LEXX) - Lexaria Bioscience began developing DehydraTECH in 2014. Since then, they have strengthened and broadened the technology to an unprecedented degree.If you cannot view the video above, please visit: https://b-tv.com/investor-alert-lexaria-bioscience-the-modern-way-to-improve-oral-drugs/Lexaria Bioscience (NASDAQ: LEXX) Lexaria Bioscience is being featured on Bloomberg on

BTV News Alert Video: Lexaria Bioscience - The Way to Improve Drugs

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study HYPER-H21-2, which features LEXX's patented DehydraTECH(TM)-processed cannabidiol (“CBD”), demonstrates up to a 23% decrease in blood pressure when compared to placebo. According to the announcement, partial results are being released today with additional blood pressure subset analyses, sleep quality and all other data analyses will be reported when complete.

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Results Of Human Clinical Study Showing Effective, Safe BP Reduction

Lexaria Bioscience Corp (NASDAQ: LEXX) is trading higher Tuesday after the company announced initial results from its human clinical study of DehydraTECH, saying the study evidences up to 23% decrease in blood pressure with DehydraTECH-CBD relative to placebo. Lexaria Bioscience noted that additional blood pressure subset analyses, sleep quality and all other data analyses are in progress and will be reported when complete.

Why Lexaria Bioscience Shares Are Trading Higher Today

Lexaria Bioscience Corp (NASDAQ: LEXX) has announced initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH-processed cannabidiol (CBD) for potential application against hypertension.  Related Content:   DehydraTECH Delivered Colchicine Can Potentially Treat COVID-19, Side Effects From mRNA Shots.

Lexaria Bioscience's Formulated Cannabidiol Lowers Blood Pressure In Hypertension Patients

Human Clinical Study HYPER-H21-2 evidences up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD relative to placebo KELOWNA, BC / ACCESSWIRE / September 7, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is extremely pleased to issue initial results from human clinical study HYPER-H21-2 evaluating DehydraTECHTM-processed cannabidiol ("CBD") for potential application against hypertension. Partial results related to blood pressure ("BP") are being released today, while additional BP subset analyses, sleep quality and all other data analyses are in progress and will be reported upon when complete.

Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period

Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve the usable fraction of known antiviral drugs that reach the bloodstream. According to a Newsfile Corp. article, this technology can be applied to rendering treatments for HIV/AIDS and other infectious diseases more effective

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets With Drug Delivery Technology

Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability KELOWNA, BC / ACCESSWIRE / July 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is extremely pleased to issue partial results from human clinical study HYPER-H21-1 evaluating DehydraTECHTM-processed cannabidiol ("CBD") for potential application against hypertension. Partial results related to blood pressure ("BP") are being released today, while additional BP subset analyses and all other data analyses including pharmacokinetic ("PK") evaluations and detailed blood chemistry work is in progress and will be released when complete.

Lexaria's DehydraTECH-CBD Lowers Blood Pressure

Lexaria's technology empowers brands nationwide in stores including Albertsons, Hudson News, and many more KELOWNA, BC / ACCESSWIRE / July 28, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its DehydraTECHTM technology has been embraced by consumer brands now available for sale in over 7,000 stores across the US. "Lexaria's technology is enabling increased market share and sales growth for our continually growing list of corporate clients," said Chris Bunka, CEO of Lexaria.

DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores

Additionally, second patent award received in Japan KELOWNA, BC / ACCESSWIRE / July 27, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that dosing has been completed in its second human clinical study of 2021. Human clinical study HYPER-H21-2 consisted of 16 human volunteers who were pre- or mildly hypertensive and received three separate doses of 150 mg each of DehydraTECHTM 2.0-enabled CBD versus a placebo (total dose of 450mg).

Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2

KELOWNA, BC / ACCESSWIRE / July 26, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the receipt of US$3,817,643 from the exercise of share purchase warrants (the "Warrants"). The Warrants were issued by the Company pursuant to its January 2021 public underwritten offering (the "Offering") whereby the shares and Warrants issued thereunder were registered pursuant to a Form S-1 Registration Statement (No.

Lexaria Receives US$3,817,643 From Warrant Exercises

Lexaria reported positive results on their DehydraTECH enabled colchicine, an anti-inflammatory, which can be used to treat COVID-19 and cardiac symptoms. The company has had additional results from other DehydaraTech enabled anti-viral medicines to treat COVID-19, for instance remdesivir and ebastine.

Lexaria Hits New 52-Week High With Positive Data On Enhanced Treatment For COVID-19

The stock price of Lexaria Bioscience Corp (NASDAQ: LEXX) increased 28.07% yesterday. This is why it happened.

LEXX Stock Increased 28.07%: Why It Happened

All objectives evaluating DehydraTECH ™ drug delivery platform successfully achieved KELOWNA, BC / ACCESSWIRE / July 22, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to review its successful 2021 antiviral drug program to date and summarize expected next steps. Lexaria's objectives in its 2021 antiviral drug examination program thus far have been to determine whether: DehydraTECH processing of compounds from leading classes of antiviral drugs for SARS-CoV-2/COVID-19, HIV/AIDS and other infectious diseases could exhibit evidence of superior oral absorption relative to controls, DehydraTECH processing of those compounds would preserve expected viral inhibitory performance upon efficacy testing in infected mammalian cells, and DehydraTECH does not alter nor degrade the drug molecules chemically as to create new molecular entities that could be challenging to guide through the regulatory approval process.

Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy

Lexaria Bioscience Corp. (NASDAQ:LEXX) shares are trading higher after the company announced its DehydraTECH significantly enhances delivery of colchicine in study VIRAL-A20-3. This study demonstrated that DehydraTECHTM enabled colchicine, the latest of several drugs Lexaria has successfully tested with known SARS-CoV-2 antiviral properties, said in the company's press release.

Why Lexaria Bioscience Is Surging Today

The stock price of Lexaria Bioscience Corp (NASDAQ: LEXX) increased by over 35% pre-market. This is why it happened.

LEXX Stock Increases Over 35% Pre-Market: Why It Happened

Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects KELOWNA, BC / ACCESSWIRE / July 21, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. This study demonstrated that DehydraTECHTM enabled colchicine, the latest of several drugs Lexaria has successfully tested with known SARS-CoV-2 antiviral properties, benefited from our proprietary formulation and processing, resulting in increased delivery: Drug Cmax* % Improvement (ng/mL) Control (ng/mL) AUClast** % Improvement (hr∙ng/mL) Control (hr∙ng/mL) Colchicine 31.97 91% (p=0.0005) 16.73 104.43 167% (p=0.0028) 38.97 Colchicine is an approved therapeutic with anti-inflammatory effects that is principally used to treat gout and conditions such as cardiac inflammation (i.e.

Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3

Lexaria Bioscience Corp (NASDAQ: LEXX) has announced results from its antiviral drug molecular characterization study VIRAL-MC21-1, completed by Canada's federally funded research organization, the National Research Council (NRC). The NRC has confirmed Lexaria's study objectives, demonstrating DehydraTECH processing and formulation technology does not create a covalently bonded new molecular entity.

Lexaria Shares Are Trading Higher On Completion Of Antiviral Drug Molecular Characterization Study

VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs KELOWNA, BC / ACCESSWIRE / July 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce results from its antiviral drug molecular characterization study VIRAL-MC21-1 recently completed by Canada's premier federally funded research organization, the National Research Council ("NRC"). The NRC has successfully confirmed Lexaria's study objectives, demonstrating DehydraTECH™ processing and formulation technology does not create a covalently bonded new molecular entity ("NME") and that each drug tested remained stable and did not undergo change in chemical structure.

News for Lexaria Bioscience Stock (LEXX)